The CanceRx mission is to accelerate clinical phase cancer research and FDA approvals by synchronizing finance with the speed of science to achieve more effective therapies capable of producing long and meaningful remission with good quality of life and affordable costs.
CanceRx deploys a new application of a well-established finance method
to fund human-phase clinical cancer research.
According to the National Cancer Institute (NCI), there are as many as 20,000 potentially life-saving basic cancer therapy patents, which due to enormous cost and high attrition rates remain dormant.
CanceRx is dedicated to multiplying the probability of success by increasing the number of projects funded through the critical human clinical trial stage with scale, diversification, and the new application of finance.